[The effect of the new metabolic preparations rikavit and mildronat on the parameters of the blood acid-base balance in humans with hypoxia].
Two antihypoxic drugs: rikavite and mildronate having different application points in the metabolic chains have been comparatively studied on three groups of patients with chronic hypoxemia developed due to chronic pulmonary heart (control group, group of patients taking rikavite, and those taking mildronate). Rikavite and mildronate are shown to improve the parameters of the acid-base state (ABS) and gases in blood of examinees. However, efficiency of the drugs' action depends on the initial degree of hypoxemia. The positive changes in the ABS parameters have occurred in examinees with pronounced hypoxemia as affected by mildronate, in this case rikavite is inefficient. The effect induced by rikavite and mildronate in examinees with less pronounced hypoxemia does not practically differ. The results testify for that cardioprotective properties of mildronate under conditions of sharp pathology of the cardiorespiratory system cause more intensive decrease in the level of arterial hypoxemia and normalization of the ABS parameters. However, with less pronounced hypoxemia the complex enzymatic action of rikavite gives a good positive effect. The advantage of rikavite in this case resides in that, stimulating succinateoxidase and glycerophosphate metabolic ways, it does not inhibit the oxidation processes of free fatty acids giving high-power efficiency.